Among the large drugmakers, Eli Lilly, AstraZeneca, Pfizer, Sanofi and Bayer are worth retaining in one’s portfolio.

With its recent US Food and Drug Administration (FDA) approval, Eli Lilly’s Ebglyss (lebrikizumab) adds a new competitor to ...

Less frequent dosing could provide Eli Lilly’s Ebglyss room to rival Sanofi and Regeneron’s blockbuster Dupixent.

Nifty moved in a tight range of 82 points, and ended slightly below the psychologically crucial level of 15,700. NEW DELHI: ...

The Nifty Pharma index closed on a positive note on Tuesday. Shares of Glenmark Pharmaceuticals Ltd.(up 3.55 per cent), Ipca ...

Ebglyss' approval highlights the opportunity that exists in the AD space, and may have potential advantages in efficacy and ...

Nuvation Bio Inc. (NYSE: NUVB), a late clinical-stage, global biopharmaceutical company tackling some of the greatest unmet needs in oncology, today announced the appointment of Philippe Sauvage as ...

The Indian pharmaceutical sector faces mixed growth with a 12% YoY and 5% QoQ rise while IPM growth is projected at 8%.

Co-development agreements involve both companies working together to develop a specific product or technology.

Discover the major biotech partnerships, collaborations and mergers and acquisitions that made headlines in September 2024.

Innovent Biologics, Inc. ("Innovent") (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high-quality medicines for the treatment of oncologic, ...

Dozens of over-the-counter acne products had very high levels of the known carcinogen benzene, even when they were taken ...